|  | V cases | V controls | BV cases | BV controls | B cases | B controls |
---|---|---|---|---|---|---|---|
Number of patients | Â | 246 | 232 | 258 | 245 | 238 | 222 |
 |  | Number (%) |  |  |  |  |  |
Age at hist. diagnosis | Median (years) | 57.1 | 51.5 | 55.7 | 51.0 | 55.9 | 51.2 |
Grade | 1 | 11 (4%) | 33 (14%) | 7 (3%) | 36 (15%) | 20 (8%) | 20 (9%) |
 | 2 | 81 (33%) | 89 (38%) | 113 (44%) | 127 (52%) | 114 (48%) | 97 (44%) |
 | 3 | 135 (55%) | 87 (38%) | 122 (47%) | 62 (25%) | 81 (34%) | 88 (40%) |
 | Unknown | 19 (8%) | 23 (10%) | 16 (6%) | 20 (8%) | 23 (10%) | 17 (8%) |
ER IHC status | Positive | 147 (60%) | 160 (69%) | 162 (63%) | 174 (71%) | 188 (79%) | 158 (71%) |
 | Negative | 99 (40%) | 72 (31%) | 96 (37%) | 71 (29%) | 50 (21%) | 64 (29%) |
PR status | Positive | 97 (39%) | 121 (52%) | 116 (45%) | 131 (53%) | 146 (61%) | 113 (51%) |
 | Negative | 149 (61%) | 111 (48%) | 142 (55%) | 114 (47%) | 92 (39%) | 109 (49%) |
HER2 status | Positive | 58 (24%) | 35 (15%) | 55 (21%) | 30 (12%) | 35 (15%) | 23 (10%) |
 | Negative | 108 (44%) | 102 (44%) | 116 (45%) | 98 (40%) | 108 (45%) | 107 (48%) |
 | Unknown | 80 (33%) | 95 (41%) | 87 (34%) | 117 (48%) | 95 (40%) | 92 (41%) |
Tumour size | <= 2Â cm | 96 (40%) | 113 (49%) | 99 (38%) | 136 (56%) | 101 (42%) | 117 (53%) |
 | >2 cm | 146 (60%) | 113 (49%) | 155 (60%) | 101 (41%) | 133 (56%) | 99 (45%) |
 | Unknown | -- -- | 6 (3%) | 4 (2%) | 8 (3%) | 4 (2%) | 6 (3%) |
Lymph nodes positive | 0 | 51 (21%) | 97 (42%) | 61 (24%) | 109 (44%) | 61 (26%) | 103 (46%) |
 | 1–3 | 74 (30%) | 81 (35%) | 64 (25%) | 80 (33%) | 70 (29%) | 64 (29%) |
 | 4+ | 74 (30%) | 28 (12%) | 81 (31%) | 28 (11%) | 64 (27%) | 29 (13%) |
 | Unknown | 47 (19%) | 26 (11%) | 52 (20%) | 28 (11%) | 43 (18%) | 26 (12%) |
Invasive subtype | NOS/no special type | 217 (88%) | 189 (81%) | 219 (85%) | 206 (84%) | 196 (82%) | 189 (85%) |
 | Ductal - mucinous | 1 (0%) | 3 (1%) | 4 (2%) | 2 (1%) | 1 (0%) | 4 (2%) |
 | Ductal - tubular | -- -- | 6 (3%) | 1 (0%) | 7 (3%) | 3 (1%) | 3 (1%) |
 | Ductal - other | 6 (2%) | 3 (1%) | 1 (0%) | 3 (1%) | 1 (0%) | 3 (1%) |
 | Lobular - classical | 14 (6%) | 23 (10%) | 19 (7%) | 22 (9%) | 29 (12%) | 13 (6%) |
 | Lobular - pleomorphic | 3 (1%) | 2 (1%) | 6 (2%) | 3 (1%) | 3 (1%) | 4 (2%) |
 | Lobular - other | 2 (1%) | 3 (1%) | 3 (1%) | 2 (1%) | 4 (2%) | 1 (0%) |
 | Other | 3 (1%) | 3 (1%) | 5 (2%) | -- -- | 1 (0%) | 5 (2%) |
Surgery type (any time) | Breast conserving | 58 (24%) | 80 (34%) | 70 (27%) | 82 (33%) | 64 (27%) | 72 (32%) |
 | Breast conserving + mastectomy | 53 (22%) | 28 (12%) | 56 (22%) | 32 (13%) | 37 (16%) | 27 (12%) |
 | Mastectomy | 106 (43%) | 110 (47%) | 99 (38%) | 120 (49%) | 115 (48%) | 114 (51%) |
 | Unknown | 29 (12%) | 14 (6%) | 33 (13%) | 11 (4%) | 22 (9%) | 9 (4%) |
Radiotherapy (adj/neo) | Yes | 168 (68%) | 140 (60%) | 197 (76%) | 126 (51%) | 194 (82%) | 125 (56%) |
 | No | 78 (32%) | 92 (40%) | 61 (24%) | 119 (49%) | 44 (18%) | 97 (44%) |
Hormone treatment (adj/neo) | Yes | 204 (83%) | 120 (52%) | 230 (89%) | 130 (53%) | 218 (92%) | 114 (51%) |
 | No | 42 (17%) | 112 (48%) | 28 (11%) | 115 (47%) | 20 (8%) | 108 (49%) |
Chemotherapy | Neo-adj only | -- -- | 3 (1%) | 3 (1%) | 67 (27%) | 8 (3%) | 3 (1%) |
 | Neo-adj and adj | 6 (2%) | 1 (0%) | 9 (3%) | 1 (0%) | 1 (0%) | 2 (1%) |
 | Adj only | 146 (59%) | 85 (37%) | 150 (58%) | 2 (1%) | 101 (42%) | 67 (30%) |
 | No | 94 (38%) | 143 (62%) | 96 (37%) | 175 (71%) | 128 (54%) | 150 (68%) |